The DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index; 63 of the 116 sources its claims cite were checked for support.
Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review
Open accessAbstract
BACKGROUND: Clinical trials are essential to the development of healthcare innovations that advance life expectancy and improve quality of life. However, there exists a pronounced disparity in ethnic representation among trial participants. This imbalance, particularly in relation to minority ethnic groups, can lead to a limited understanding of how therapies affect diverse populations. The present systematic literature review (SLR) aims to identify the factors that both hinder and facilitate the participation of minority ethnic groups in clinical trials. METHODS: This review involved a systematic search of keywords across four databases: Web of Science, PubMed, CINAHL Plus and The Cochrane Library. The review was not restricted by language or study site; however, the date of publication was limited between 1st January 2017 and 1st October 2022. Studies discussing or outlining the involvement of minority ethnic groups in clinical trials, and those outlining inclusive recruitment and participation procedures were targeted. RESULTS: A total of 43 articles were included in the review. Of these, 36 articles were from the United States (US), 20 articles reported on oncology trials and 39 articles reported information from the patient's perspective. Reported barriers included a lack of researchers from minority ethnic groups implementing and conducting clinical research, inadequate funding for clinical trial efforts in geographical areas serving minority populations and a lack of awareness and education among research staff regarding which underrepresented groups to target for recruitment and the strategies to employ in reaching out to them. Several recommendations were suggested by the articles included in the review to address these barriers. Prominently, the use of patient navigators or community liaison roles was highly recommended as a way of supporting patients through the research recruitment process. The articles also highlighted the benefits of translating study materials and interventions into multiple languages and actively involving diverse communities in the development of health education materials. Lastly, leveraging technologies to address socioeconomic barriers, such as the use of virtual approaches to avoid lengthy travel, may also help to improve diversity in trials. CONCLUSIONS: Ensuring representation of minority ethnic groups in clinical trials is critical to developing therapies with generalisable efficacies. While progress has been made in enhancing outreach of wider racial groups and fortifying educational resources, there remains a pressing need to delve deeper into the obstacles impeding the recruitment of a diverse participant base, particularly in regions outside the US, where relevant studies are scarce. REGISTRATION: The review protocol was registered on PROSPERO (CRD42022368106) (1).
Overview
CoChat Summary
TL;DR
This systematic review synthesized 43 articles on barriers and enablers of clinical trial participation among adult patients from minority ethnic groups, finding that evidence is concentrated in the US and especially in oncology. It identifies mistrust, communication/language problems, socioeconomic constraints, and lack of culturally competent outreach as recurring barriers, while patient navigators, community liaisons, translated materials, and community-engaged recruitment are recurring enablers.
Key findings
- The review included 43 articles; 36 were from the US, 20 focused on oncology trials, and 39 reported from the patient perspective.
- Evidence quality was moderate overall: the MMAT average score was 4, and 12 articles scored below 3.
- Reported barriers included lack of researchers from minority ethnic groups, inadequate funding in areas serving minority populations, limited staff awareness of which groups to target and how, plus implicit bias, language barriers, and socioeconomic challenges such as unstable employment, childcare, low income, and transport problems.
- Recurrent enablers/recommendations were patient navigators or community liaisons, translation of study materials and interventions into multiple languages, involving diverse communities in health education materials, and virtual approaches to reduce travel burden.
Methods
- Systematic review using PRISMA, with a protocol registered on PROSPERO (CRD42022368106).
- Searches were conducted in Web of Science, PubMed, CINAHL Plus, and The Cochrane Library/CENTRAL, for studies published between 1 January 2017 and 1 October 2022, with no language or study-site restriction.
- Included peer-reviewed empirical studies about adult minority ethnic groups’ involvement in clinical trials or inclusive recruitment/participation processes; evidence was synthesized using narrative synthesis, and study quality was appraised with the MMAT.
Limitations
- The paper states that it was limited to empirical articles, excluding grey literature and non-empirical articles, which could have added further reflections on disparities.
- It also states that paediatric studies were excluded, so the findings do not apply to children.
- Evident from the text: the evidence base is heavily US-centered (36/43 articles) and sparse outside the US, so generalisability to other countries is limited (stated in the paper).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
30 Valid · 5 Not valid · 21 Not checked · 46 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“and American Indian and Alaska Natives accounted for a mere 1.3% of trial participants [19].”
§ Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review > Introduction
What the sources say
- Disputedcites [19] Reihl SJ, Patil N, Morshed RA, Mehari M, Aabedi A, Chukwueke UN, et al. A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro Oncol. 2022;24(8):1341–9. https://doi.org/10.1093/neuonc/noac011. sourceExperimental — accuracy not yet measured
The Results section reports that American Indian/Alaska Native participants accounted for 0.2% of participants in studies reporting race. It assigns the 1.3% figure to Asian/Pacific Islander participants, not American Indian/Alaska Native participants. Page numbers were not provided in our copy. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A frequently cited reason for the underrepresentation of certain minority ethnic groups in clinical trials is a pervasive mistrust in the healthcare system. This is often attributed to historical instances of mistreatment and exploitation.”
§ Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review > Introduction
What the sources say
- Partly supportedcites [3] Nouvini R, Parker PA, Malling CD, Godwin K, Costas-Muñiz R. Interventions to increase racial and ethnic minority accrual into cancer clinical trials: A systematic review. Cancer. 2022;128(21):3860–9. https://doi.org/10.1002/cncr.34454. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) identifies mistrust as an extensively studied barrier to minority enrollment in cancer clinical trials. It does not explicitly describe that mistrust as pervasive throughout the healthcare system or attribute it to historical mistreatment and exploitation; its references to the Tuskegee study do not establish that full claim. (LLM, conf=0.84)
- Supportedcites [8] Sneed RS, Mason M, Williams JN, Sinnette C, Taber K, Mancera-Cuevas K, et al. Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers. Arthritis Care Res. 2021;73(10):1387–95. https://doi.org/10.1002/acr.24635. source
The Discussion says historical exploitation of Black individuals in research has embedded mistrust of researchers and the research process in Black communities. The Results identify mistrust linked to historical racism as a barrier to clinical-trial participation among Black patients with SLE. These passages support the cited statement as a broad explanation for underrepresentation, rather than a claim about every minority ethnic group. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [9] Cocroft S, Welsh-Bohmer KA, Plassman BL, Chanti-Ketterl M, Edmonds H, Gwyther L, et al. Racially diverse participant registries to facilitate the recruitment of African Americans into presymptomatic Alzheimer’s disease studies. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2020;16(8):1107–14. https://doi.org/10.1002/alz.12048. source
- Not checked — no full text of the sourcecites [10] Dance KV, Imbody CB, Chen L, McNeill L, Payne JB, Flowers CR. Perceptions of clinical care and research among African-American patients with lymphoma. Leuk Lymphoma. 2021;62(8):1860–8. https://doi.org/10.1080/10428194.2021.1892092. source
- Supportedcites [11] Rogers CR, Matthews P, Brooks E, Le Duc N, Washington C, McKoy A, et al. Barriers to and Facilitators of Recruitment of Adult African American Men for Colorectal Cancer Research: An Instrumental Exploratory Case Study. JCO oncology practice. 2021;17(5):e686–94. https://doi.org/10.1200/OP.21.00008. source
The Background identifies medical mistrust as a main barrier to African Americans’ participation in research and clinical trials and links that distrust to historical events such as the Tuskegee study. The Discussion likewise describes mistrust stemming from historical mistreatment in medical research. The paper’s specific focus is African American men, who fit the claim’s reference to certain minority ethnic groups. (LLM, conf=0.88)
- Partly supportedcites [12] Thetford K, Gillespie TW, Kim YI, Hansen B, Scarinci IC. Willingness of Latinx and African Americans to Participate in Nontherapeutic Trials: It Depends on Who Runs the Research. Ethnicity & Disease. 2021;31(2): 263–272. https://doi.org/10.18865/ed.31.2.263. sourceExperimental — accuracy not yet measured
The Introduction identifies distrust and historical medical maltreatment as possible explanations for low participation, and the Discussion describes this as a continuing belief among providers and researchers. But the paper does not establish pervasive mistrust as the reason for underrepresentation: its Conclusion reports trust among the populations studied and identifies not being invited as the primary reason they had not participated. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [13] Henrietta Lacks: science must right a historical wrong. Henrietta Lacks: science must right a historical wrong. Nature. 2020;585(7823): 7–7. https://doi.org/10.1038/d41586-020-02494-z. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Historically, there has been a lack of ethnic representation in clinical trial participants; minority ethnic groups have often been underrepresented or omitted from research [3, 4].”
§ Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review > Introduction
What the sources say
- Supportedcites [3] Nouvini R, Parker PA, Malling CD, Godwin K, Costas-Muñiz R. Interventions to increase racial and ethnic minority accrual into cancer clinical trials: A systematic review. Cancer. 2022;128(21):3860–9. https://doi.org/10.1002/cncr.34454. source
The Introduction states that most studies leading to cancer-treatment advances lacked adequate racial and ethnic minority representation and that minority patients have been underrepresented in many clinical trials. It also reports disproportionately low enrollment rates for Black and Latino patients. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [4] Shapiro M. Disparity of Equitable Representation in Cancer Clinical Trials: Nursing Perspectives. Clin J Oncol Nurs. 2022;26(4):449–54. https://doi.org/10.1188/22.CJON.449-454. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A 2019 review revealed that of the cancer therapies approved by the US Food and Drug Administration (FDA) between 2008 and 2018, only 63% of the relevant trials reported race-related data [18].”
§ Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review > Introduction
What the sources say
- Supportedcites [18] Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol. 2019;5(10): e191870. https://doi.org/10.1001/jamaoncol.2019.1870. source
The Abstract reports that 145 of 230 trials (63.0%) supporting FDA oncology drug approvals reported on at least one race. It defines the approval period as July 2008 through June 2018, matching the citing sentence’s rounded date range. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2022, a study by Reihl et al. revealed that, almost 30 years after the Revitalization Act was put in place in the US, White males were still overrepresented in neuro-oncology clinical trials, accounting for more than 90% of trial participants.”
§ Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review > Introduction
What the sources say
- Partly supportedcites [19] Reihl SJ, Patil N, Morshed RA, Mehari M, Aabedi A, Chukwueke UN, et al. A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro Oncol. 2022;24(8):1341–9. https://doi.org/10.1093/neuonc/noac011. sourceExperimental — accuracy not yet measured
The Abstract reports that White participants accounted for 91.7% of trial participants, while men accounted for 62.5%; it does not say White men accounted for more than 90%. The Discussion says White men remained disproportionately represented in trials for adult neuro-epithelial CNS tumors, supporting the overrepresentation point but not the claimed percentage for that group. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
35 more claims · 8 with their cited sources checked
Create a free account to see all 102 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 39
- It may state two separate claims as one. 43
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092 · cited 1×
“Rayyan facilitated the screening by presenting citation details, titles and abstracts of each publication [28].”
Pace, R., Pluye, P., Bartlett, G., Macaulay, A. C., Salsberg, J., Jagosh, J., & Seller, R. (2012) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2011.07.002 · Cited by 1,331
Loree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., & Raghav, K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1870 · Cited by 570 · cited 1×
“A 2019 review revealed that of the cancer therapies approved by the US Food and Drug Administration (FDA) between 2008 and 2018, only 63% of the relevant trials reported race-related data [18].”
Souto, R. Q., Khanassov, V., Hong, Q. N., Bush, P. L., Vedel, I., & Pluye, P. (2015) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2014.08.010 · Cited by 375 · cited 1×
“The methodological quality of the empirical studies was critically appraised using the Mixed Methods Appraisal Tool (MMAT) [30, 31].”
Bower, P., Brueton, V., Gamble, C., Treweek, S., Smith, C. T., Young, B., & Williamson, P. (2014) · Trials · doi:10.1186/1745-6215-15-399 · Cited by 369
Witham, M. D., Anderson, E., Carroll, C., Dark, P. M., Down, K., Hall, A. S., Knee, J., Maier, R. H., Mountain, G. A., Nestor, G., et al. (2020) · Trials · doi:10.1186/s13063-020-04613-7 · Cited by 259 · cited 1×
“A recent initiative funded by the NIHR, named “Inno-vations in Clinical Trial Design and Delivery for the Under-served” (INCLUDE), proposed a framework to increase the number of underserved trial participants from minority ethnic groups [24–26].”
Ortega, V. E., & Meyers, D. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.040 · Cited by 237 · cited 1×
“The consequences of such underrepresentation are profound, leading to disparities in access to treatment and significant knowledge gaps regarding how certain drugs and therapies affect different ethnic populations [7, 8].”
Otado, J., Kwagyan, J., Edwards, D., Ukaegbu, A., Rockcliffe, F., & Osafo, N. (2015) · Clinical and Translational Science · doi:10.1111/cts.12285 · Cited by 231 · cited 1×
“For instance, the introduction of diversity quotas for trials may result in recruitment taking longer and increase the cost of delivering the study, ultimately reducing the benefit of the research to all patients [76].”
Differences in cancer incidence by broad ethnic group in England, 2013–2017
Delon, C., Brown, K. F., Payne, N. W. S., Kotrotsios, Y., Vernon, S., & Shelton, J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01718-5 · Cited by 137
COVID-19 and ethnicity: who will research results apply to?
Treweek, S., Forouhi, N. G., Narayan, K. M. V., & Khunti, K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31380-5 · Cited by 119 · cited 2×
“…patients, the reviewed studies produced a significant amount of data on how historical and institutional forms of racism acted as barriers to trial participation [9–11, 37, 53, 55], exemplified by events like the US Tuskegee Syph-ilis study and its unethical treatment of Black patients [74].”
Cited by
Enhancing randomized clinical trials with digital twins
Akbarialiabad, H., Pasdar, A., Murrell, D. F., Mostafavi, M., Shakil, F., Safaee, E., Leachman, S. A., Haghighi, A., Tarbox, M. B., Bunick, C. G., et al. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00592-0 · Cited by 70
Gogoi, M., Baggaley, R. F., Silva, L., Lal, Z. Z., Reilly, H., Modhwadia, V., Pan, D., Bird, P. W., Nellums, L. B., & Pareek, M. (2025) · Health Expectations · doi:10.1111/hex.70337 · Cited by 5
Thomas, T., Jones, L. L., Dawson, S., Houghton, C., Hunter, A., O'Connell, N., & Biesty, L. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112202 · Cited by 2
Sidhu, R., Selvamogan, A., & Boddy, A. (2026) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2026.0021 · Cited by 3
Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI
Welchman, A. E., & Kourtzi, Z. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100397 · Cited by 3
“Clinical trials and research cohorts generally overrepresent majority populations [55,56] creating the potential for models to perform poorly when presented with data from underrepresented groups.”
Metadata
- Authors
- Alarcón Garavito, G. A., Gilchrist, K., Ciurtin, C., Khanna, S., Chambers, P., McNally, N., Merivale, E., Carr, E., Yu, R., & Vindrola-Padros, C.
- Affiliations
- University College London (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Roche (United Kingdom) (GB)
- Venue
- Trials
- Published
- 2025-02-22
- Volume
- 26
- Issue
- 1
- Pages
- 65-65
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC11846389
- OpenAlex
- W4407820176
- Cited by
- 42
- References
- 68
- Citations by year
- 2026: 32 · 2025: 10
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Trials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Social Sciences › Anthropology › Race, Genetics, and Society
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Cultural Competency in Health Care
- Keywords
- clinical trial participation, ethnic minorities, underrepresented groups, recruitment barriers, patient navigators, community liaison, language translation, virtual clinical trials, cancer clinical trials, patient perspectives, health equity
- MeSH terms
- Adult, Clinical Trials as Topic, Ethnicity, Humans, Health Knowledge, Attitudes, Practice, Minority Groups, Patient Participation, Patient Selection, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review. https://app.cochat.ai/papers/10.1186/s13063-025-08769-y
- The paper
- Alarcón Garavito, G. A., Gilchrist, K., Ciurtin, C., Khanna, S., Chambers, P., McNally, N., Merivale, E., Carr, E., Yu, R., & Vindrola-Padros, C. (2025). Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review. Trials. https://doi.org/10.1186/s13063-025-08769-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
